[1] GONG S W, ZHANG M, DENG X L， et al. Ideas on the definition of rare disease and orphan drugs in China [J]. Chin J New Drugs(中国新药杂志)，2006,15(15)：1225-1229.
[2] TAO Y. The current situation of orphan drug regulation in the United States[J]. Chin Pharm J(中国药学杂志),2001,36(9)：634-636.
[3] GUAN X D, SHI L W. Analysis on the establishment of national drug policy in China[J]. Chin Pharm J(中国药学杂志),2009, 44(2)：158-160.
[4] LI H T. Analysis on the accessibility of drugs in China [J]. Chin Health Serv Management（中国卫生事业管理）,2009(9)：612-614.
[5] FENG J H. Public health crisis, accessibility of drugs and its parallel imports [J].National Judges College Law J（法律适用），2004,12（25）：15-18.
[6] GONG S W. Study of Management Strategies of Improving Access to Orphan Drugs in China [D].Wuhan： Huazhong Univeristy of Science and technology 2008.1-122.
[7] YANG C L. Incidence survey of leukemia in china [J]. Acta Acad Med Sin（中国医学科学院学报）,1992,14(1)：12-19.
[8] LL S. Facts 2010-2011[J/OL]. New York：LLS,2011：[2011-05-16]. http：//www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.
[9] MOHC. Year Book of Health in the People′S Republic of China[DB/OL].BeiJing：peking union medical college press,2010[2011-05-16]. http：//www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2010/index2010.html.
[10] US. Census Bureau. Statistical Abstract of the United States：2007[DB/OL]. New York： U.S. Census Bureau,2007[2011-05-16]. http：//www.census.gov/prod/www/statistical-abstract-us.html.
[11] FDA. FDA Application Search Orphan Drug Designations and Approvals[DB/OL].New York： FDA,2011[2011-05-16] http：//www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm.
[12] SFDA. Data Search[DB/OL]. BeiJing：SFDA,2011[2011-05-16].http：//app1.sfda.gov.cn/datasearch/face3/dir.html.
[13] ZHANG R W, HU S L. A comparative study of international price for pharmaceuti-cals medicine price [J]. Chin Health Econ（中国卫生经济）,2001,20(2)：26-28.
[14] VILLA S, COMPAGNI A, REICH M R. Orphan drug legislation： lessons for neglected tropical diseases[J]. Int J Health Plann Mgmt, 2009,24（3）：27-42.
[15] SFDA The Southern Institute of Medical Economics. Database[DB/OL]. GuangDong：The Southern Institute of Medical Economics,2011[2011-05-16].http：//www.meinet.com.cn：8080/Query/MedicinePrice/.
[16] RxUSA Pharmacy. Database[DB/OL]. New York：RxUSA,2011[2011-05-16].http：//www.rxusa.com/.
[17] ZHANG J G. A background and present situation of USA orphan drug[J]. Chin J Pharmacoepiolemiol（药物流行病学杂志）， 2002（3）：153-154.
[18] DING J X, ZHAO M. The comparative study on supervision and incentive policies of Sino-US during the innovative drug R&D[J]. Chin J New Drugs（中国新药杂志）,2009,18(5)：387-392.
[19] ZHAO C X, XU F, WANG Y， et al. Ideas on the strategy in establishing orphan drug managing system [J]. Med Philosophy(医学与哲学)，2003,24(7)：41-43.